GZBL(SZ:002424) Xin Lang Cai Jing·2025-10-15 09:41Core Viewpoint - Guizhou BaiLing's wholly-owned subsidiary has received approval for clinical trials of a new traditional Chinese medicine for type 2 diabetes, enhancing the company's product line in diabetes treatment [1] Group 1: Clinical Trial Approval - The company announced that its subsidiary BaiLing YuXiu received the "Drug Clinical Trial Approval Notice" from the National Medical Products Administration, allowing the clinical trial of Tang Ning Tong Luo Pian for type 2 diabetes [1] - This approval is based on over ten years of research and development, with the product already used in clinical settings since 2014 as a hospital preparation, accumulating significant human usage experience [1] Group 2: Product Development and Market Position - Tang Ning Tong Luo Pian is classified as a Class 1 traditional Chinese medicine and is notable for being the first to transition from a hospital preparation to a new drug under the "Special Regulations on the Registration of Traditional Chinese Medicine" [1] - The drug has demonstrated good efficacy in treating both treated and untreated type 2 diabetes patients by adjusting endocrine functions and improving disease symptoms, thus reversing biochemical indicators [1]